MoCRA Safety File for Private Label Peptide Serums

Identify the responsible person and each facility

Map the brand, label distributor, contract manufacturer, packer and any processing site. Confirm who is the responsible person for the marketed product and who handles facility registration where required. Do not copy a facility registration number into marketing as an approval claim. Document small-business exemption analysis separately because exemptions have limits and do not remove the basic duty to market a safe cosmetic.

Build safety substantiation around the actual formula

Keep the quantitative formula, raw-material specifications, supplier safety data, exposure assumptions, impurities, intended use and qualified safety assessment together. Peptide supplier brochures do not establish finished-product safety. Consider the delivered carrier, preservatives and companion actives. Maintain records supporting adequate substantiation using scientifically robust information appropriate to the product.

Control ingredient and product listing data

Ensure the ingredient declaration matches the commercial formula and supplier compositions. Stock solutions can contain carriers and preservatives omitted from a marketing worksheet. Establish a change-control route from R&D and purchasing to the person maintaining US product listing. Annual updates and formulation changes cannot be managed reliably from artwork alone.

Link GMP records to peptide risks

Batch records should identify exact peptide product codes and lots, addition temperature, pH, mixing and yield. Maintain calibration, sanitation, water, microbiology, release and deviation records. A shared INCI does not make two suppliers interchangeable. If the OEM substitutes a grade, assess composition, safety, stability and label impact before release.

Keep claims in cosmetic territory

Avoid claims to treat disease, heal tissue, alter body structure or provide injection-equivalent effects. Use appearance and conditioning language supported by the finished product. US drug classification can be triggered by intended use communicated through websites, labels and social content, not only the carton. Review distributor and influencer copy as part of claim control.

Prepare complaint and adverse-event handling

Define intake channels, product and lot identification, seriousness assessment, medical follow-up, record retention and escalation. The responsible person has reporting duties for serious adverse events within required timelines. Train customer service to preserve the label, photographs and contact details instead of replying only with a refund. Trend non-serious complaints because clusters can reveal pump, contamination or tolerance problems.

Make the OEM document package explicit

The quality agreement should state who supplies batch COA, microbiology, stability, challenge test, safety information, facility details, change notices and complaint investigation. Confirm access to records if the relationship ends. A low-MOQ private-label package that provides only an INCI and invoice is not a complete compliance file.

Audit the file before launch

Reconcile formula, INCI, label, product listing data, manufacturer records and safety assessment. Check company contact information and complaint pathway. Verify supporting tests apply to the final package and formula. Record open items and responsible owners; do not treat a generic compliance certificate as closure for missing evidence.

A useful dossier index

I use a controlled index with sections for product identity, formula, raw materials, manufacturing, specifications and release, stability and preservation, safety assessment, claims, label, listing, complaints and change history. Each file shows product code, version and approval date. Cross-reference the exact peptide supplier code so a purchasing change triggers review. Keep signed reports rather than screenshots from a portal. The structure is not mandated as one universal template, but it makes inspection and handover practical. More importantly, it shows where evidence is absent. A neatly named empty folder is not substantiation, and a supplier statement cannot replace the brand's assessment of the finished product.

Change control after the first product listing

A listed formula still changes in real operations: a peptide carrier is revised, a preservative supplier moves site, a bottle resin changes or the brand adds a new claim. Route each proposal through formula, safety, stability, label and listing impact review before purchase or production. Record whether the change requires updated product information, new substantiation or additional testing. Keep effective dates so complaints can be linked to the correct version. Ask the OEM to identify changes proactively rather than discovering them from a different COA after filling. Annual listing maintenance is easier when the underlying formula and supplier records are controlled. Without that discipline, the regulatory entry, carton and manufactured product can describe three different compositions.

Questions buyers also ask

Does FDA approve private label peptide serum before sale?

No. Cosmetic labels and claims are generally not pre-approved; responsible companies must comply and maintain appropriate safety support.

Who is the responsible person for a private label cosmetic?

It is generally the manufacturer, packer or distributor whose name appears on the label, subject to the statutory definition and project facts.

What records support peptide serum safety?

Formula, ingredient data, exposure and safety assessment, manufacturing controls, stability, microbiology, package and complaint records should form a coherent file.

Selected source

Use this source as context; finished-product decisions require product-specific assessment.

• FDA overview of MoCRA